Pharmaceutical

Grey Wolf gains $50m boost for antigen modulation tech

Grey Wolf Therapeutics has concluded an oversubscribed $50m in Series B financing expansion to advance its antigen modulation technology.

May 25, 2024 - 04:00
Grey Wolf gains $50m boost for antigen modulation tech
Grey Wolf Therapeutics has concluded an oversubscribed $50m in Series B financing expansion to advance its antigen modulation technology.
Read the original article

Tags:

Previous Article

FDA advisory committee reviews Novo Nordisk insulin icodec for T1D

Next Article

Cystic fibrosis: global clinical trials landscape and treatments

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Janssen submits sBLA to FDA for NSCLC combination therapy

Janssen submits sBLA to FDA for NSCLC combination therapy

Aug 28, 2023

Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence

Biogen completes $1.15bn HI-Bio acquisition to expand i...

Jul 4, 2024

AstriVax received €2.5 million government grant for thermostable vaccines

AstriVax received €2.5 million government grant for the...

May 30, 2023